Microbot Medical Strengthens LIBERTY® Endovascular Robotic System Position with Landmark Study Publication

Key Highlights from the Report

• Peer-Reviewed Publication: Microbot Medical Inc. (Nasdaq: MBOT) announced the publication of pivotal clinical trial results for its LIBERTY® Endovascular Robotic System in the Journal of Vascular and Interventional Radiology (JVIR), a leading peer-reviewed journal in the field.
• Study Details: The published article, titled “In Vivo Evaluation of a Disposable Endovascular Robotic System for Arterial Peripheral Vascular Interventions: A Multicenter Feasibility Study,” features Dr. Francois Cornelis, a prominent interventional radiologist, as the lead author and principal investigator.
• Clinical Validation: The ACCESS-PVI study, completed in 2025, underwent rigorous independent peer review and was previously presented at the Society of Interventional Radiology (SIR) annual meeting in April 2025. This peer-reviewed publication is considered the gold standard for clinical validation.
• FDA Clearance: LIBERTY® achieved U.S. FDA clearance in September 2025 for peripheral endovascular procedures, marking a major regulatory milestone.
• Market Release: Microbot initiated a limited market release of LIBERTY® in late 2025 and is planning a full market release at the SIR conference in April 2026, aiming to drive broader commercial adoption.
• Unique Offering: LIBERTY® is currently the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is engineered for precise vascular navigation and designed to reduce radiation exposure and physical strain for operators.

Important Information for Shareholders

• Potential Price Sensitivity: The peer-reviewed publication and FDA clearance are significant catalysts that may positively impact investor sentiment and share value, as they validate the LIBERTY® system’s clinical efficacy and market potential.
• Commercialization Progress: The transition from limited to full market release, especially at a major industry conference, signals accelerating commercialization. This is likely to be closely watched by investors for potential revenue growth and adoption rates.
• Competitive Advantage: LIBERTY®’s status as the only FDA-cleared single-use robotic system for its indication gives Microbot Medical a distinct competitive edge, which may lead to increased market share and pricing power in the endovascular robotics sector.
• Risks and Uncertainties: Investors should be aware of risks including commercialization challenges, regulatory uncertainties, geopolitical impacts (especially in relation to ongoing hostilities in Israel and neighboring regions), and maintenance of intellectual property rights. These factors may affect future performance and share value.

Detailed Summary for Investors

Microbot Medical Inc. has achieved a major milestone with the publication of its pivotal ACCESS-PVI study results in the Journal of Vascular and Interventional Radiology. This peer-reviewed article not only confirms the robust methodology and clinical data supporting LIBERTY®, but also provides independent validation from leading experts in the field. The study, led by Dr. Francois Cornelis, underscores the system’s feasibility, safety, and effectiveness for arterial peripheral vascular interventions.

The LIBERTY® system received FDA clearance in September 2025, enabling its use in peripheral endovascular procedures across the United States. Microbot began limited commercial rollout in late 2025 and has scheduled a full launch at the SIR conference in April 2026, leveraging the industry event to build broader awareness and adoption.

LIBERTY® distinguishes itself as the world’s first FDA-cleared, single-use, remotely operated robotic system for precision vascular navigation. Its design aims to minimize radiation exposure and operator fatigue, addressing critical unmet needs in the interventional radiology community. Backed by a robust intellectual property portfolio, Microbot is positioned to advance the future of endovascular care.

While these developments are likely to be seen as positive by investors, shareholders should remain mindful of risks related to commercialization, regulatory pathways, geopolitical dynamics, and IP protection. Ongoing clinical evidence generation and successful market penetration will be key drivers of share value moving forward.

For more information, shareholders and interested parties can contact Microbot Medical at [email protected] or [email protected].

Disclaimer

The information provided above is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. Investors are encouraged to review Microbot Medical’s filings with the Securities and Exchange Commission for a full discussion of risk factors. The author assumes no responsibility for any investment decisions made based on this article.

View Microbot Medical Inc. Historical chart here